AbbVie Competitors

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Risk and Volatility

Johnson & Johnson has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Johnson & Johnson and AbbVie, as reported by MarketBeat.com.

Johnson & Johnson currently has a consensus price target of $190.3750, indicating a potential upside of 10.29%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts plainly believe Johnson & Johnson is more favorable than AbbVie.

Earnings & Valuation

This table compares Johnson & Johnson and AbbVie's gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

66.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 66.0% of AbbVie shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.5%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Johnson & Johnson and AbbVie's net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats AbbVie on 9 of the 16 factors compared between the two stocks.

Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Earnings & Valuation

This table compares Pfizer and AbbVie's gross revenue, earnings per share and valuation.

Pfizer has higher earnings, but lower revenue than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Pfizer and AbbVie, as reported by MarketBeat.com.

Pfizer currently has a consensus price target of $43.0833, indicating a potential downside of 1.97%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Pfizer.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.5%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Pfizer pays out 70.3% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

64.1% of Pfizer shares are held by institutional investors. Comparatively, 66.0% of AbbVie shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and AbbVie's net margins, return on equity and return on assets.

Risk and Volatility

Pfizer has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Summary

AbbVie beats Pfizer on 14 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Eli Lilly and and AbbVie's revenue, earnings per share and valuation.

Eli Lilly and has higher earnings, but lower revenue than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Eli Lilly and and AbbVie, as reported by MarketBeat.

Eli Lilly and currently has a consensus price target of $231.2857, indicating a potential downside of 6.10%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given AbbVie's higher possible upside, analysts plainly believe AbbVie is more favorable than Eli Lilly and.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

81.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 66.0% of AbbVie shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Eli Lilly and and AbbVie's net margins, return on equity and return on assets.

Volatility and Risk

Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Eli Lilly and beats AbbVie on 10 of the 18 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Merck & Co., Inc. and AbbVie's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Merck & Co., Inc. and AbbVie's revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Merck & Co., Inc. and AbbVie, as reported by MarketBeat.

Merck & Co., Inc. currently has a consensus price target of $94.7238, indicating a potential upside of 23.27%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given Merck & Co., Inc.'s higher possible upside, equities research analysts plainly believe Merck & Co., Inc. is more favorable than AbbVie.

Institutional & Insider Ownership

71.7% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 66.0% of AbbVie shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

AbbVie beats Merck & Co., Inc. on 9 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

71.5% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 66.0% of AbbVie shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 2.9%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Bristol-Myers Squibb pays out 30.4% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bristol-Myers Squibb and AbbVie, as reported by MarketBeat.com.

Bristol-Myers Squibb presently has a consensus price target of $74.30, suggesting a potential upside of 8.34%. AbbVie has a consensus price target of $121.2369, suggesting a potential upside of 3.76%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than AbbVie.

Valuation & Earnings

This table compares Bristol-Myers Squibb and AbbVie's revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and AbbVie's net margins, return on equity and return on assets.

Summary

AbbVie beats Bristol-Myers Squibb on 12 of the 18 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Risk & Volatility

AbbVie has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Institutional & Insider Ownership

66.0% of AbbVie shares are owned by institutional investors. Comparatively, 90.0% of Zoetis shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Zoetis pays out 26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Zoetis has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AbbVie and Zoetis, as provided by MarketBeat.

AbbVie presently has a consensus target price of $121.2369, suggesting a potential upside of 3.76%. Zoetis has a consensus target price of $188.75, suggesting a potential downside of 6.94%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Zoetis.

Valuation & Earnings

This table compares AbbVie and Zoetis' top-line revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Zoetis' net margins, return on equity and return on assets.

Summary

AbbVie beats Zoetis on 10 of the 17 factors compared between the two stocks.